COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Mirtazapine in Alzheimer-associated Weight Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01505504
Recruitment Status : Completed
First Posted : January 6, 2012
Last Update Posted : January 6, 2012
Information provided by (Responsible Party):
Kurt Segers, Brugmann University Hospital

Brief Summary:

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.

The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Condition or disease Intervention/treatment
Alzheimer's Disease Weight Loss Mixed Dementia Dementia Drug: mirtazapine

Layout table for study information
Study Type : Observational
Actual Enrollment : 22 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study
Study Start Date : January 2004
Actual Primary Completion Date : November 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Mirtazapine

Intervention Details:
  • Drug: mirtazapine
    30 mg at bedtime
    Other Name: Remergon

Primary Outcome Measures :
  1. body weight [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with established diagnosis of AD or mixed dementia with reported weight loss

Inclusion Criteria:

  • AD or mixed dementia
  • documented weight loss
  • mirtazapine 30 mg explicitly prescribed against weight loss

Exclusion Criteria:

  • no treatment compliance
  • other causes of weight loss
  • other interventions against weight loss

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01505504

Layout table for location information
CHU Brugmann
Brussels, Belgium, 1020
Sponsors and Collaborators
Brugmann University Hospital
Layout table for additonal information
Responsible Party: Kurt Segers, Principal Investigator, Brugmann University Hospital Identifier: NCT01505504    
Other Study ID Numbers: MIRTA-2012
First Posted: January 6, 2012    Key Record Dates
Last Update Posted: January 6, 2012
Last Verified: January 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Body Weight
Weight Loss
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Body Weight Changes
Antidepressive Agents
Psychotropic Drugs
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Adrenergic alpha-2 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists